AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2671617 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 0
Study 2671617 — intervention group
Group type: COMPARATOR
Intervention: Diuretic therapy
Number of subjects: 0
Study 62265 — intervention group
Group type: EXPERIMENTAL
Intervention: Total nodal irradiation (T.N.I.)
Number of subjects: 117
Study 62265 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy (MOPP: mustine hydrochloride, vincristine, procarbazine, and prednisone)
Number of subjects: 117
Study 62265 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy (MOPP)
Number of subjects: 117
Study 28834381 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (n = 84)
Number of subjects: 103
Study 28834381 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 19)
Number of subjects: 103
Study 25993549 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted workplace intervention (participatory ergonomics, physical training, CBT)
Number of subjects: 594
Study 23287638 — intervention group
Group type: EXPERIMENTAL
Intervention: α-tocopherol
Number of subjects: 0
Study 23287638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20082117 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab plus DTIC
Number of subjects: 72
Study 20082117 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab alone
Number of subjects: 72
Study 19920428 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided FNB
Number of subjects: 107
Study 19920428 — intervention group
Group type: COMPARATOR
Intervention: US-guided FNB with nerve stimulation (USNS)
Number of subjects: 107
Study 19920428 — intervention group
Group type: COMPARATOR
Intervention: USNS
Number of subjects: 107
Study 17305788 — intervention group
Group type: EXPERIMENTAL
Intervention: AQUACEL Hydrofiber dressings containing ionic silver (AQAg)
Number of subjects: 134
Study 17305788 — intervention group
Group type: COMPARATOR
Intervention: Algosteril calcium alginate (CA) dressings
Number of subjects: 134
Study 15633440 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary angioplasty (PCI)
Number of subjects: 21
Study 15633440 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic therapy (TT)
Number of subjects: 21
Study 11137283 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ritanserin for 4 weeks
Number of subjects: 80
Study 11137283 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 80
Study 9392620 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-infusion BSO alone
Number of subjects: 21
Study 9392620 — intervention group
Group type: EXPERIMENTAL
Intervention: BSO plus melphalan (15 mg/m2)
Number of subjects: 21
Study 9392620 — intervention group
Group type: EXPERIMENTAL
Intervention: BSO plus melphalan
Number of subjects: 21
Study 9392620 — intervention group
Group type: COMPARATOR
Intervention: BSO
Number of subjects: 21
Study 7639365 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl
Number of subjects: 90
Study 7639365 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine
Number of subjects: 90
Study 7639365 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fentanyl and clonidine
Number of subjects: 90
Study 7639365 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 90
Study 30674430 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% (GPEC)
Number of subjects: 30
Study 30674430 — intervention group
Group type: COMPARATOR
Intervention: Saline (GC)
Number of subjects: 30
Study 27890777 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological wellbeing assessed with the Depression Anxiety and Stress Scale (DASS)
Number of subjects: 41
Study 27890777 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function assessed using the Delayed Matching to Samples (DMS) test from the Cambridge Neuropsychological Test Automated Battery (CANTAB)
Number of subjects: 41
Study 25762426 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation and guided imagery
Number of subjects: 37
Study 25762426 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 37
Study 23415313 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC/MMF
Number of subjects: 78
Study 23415313 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC/SRL
Number of subjects: 78
Study 23415313 — intervention group
Group type: EXPERIMENTAL
Intervention: SRL/MMF
Number of subjects: 78
Study 23415313 — intervention group
Group type: COMPARATOR
Intervention: TAC/MMF vs TAC/SRL
Number of subjects: 78
Study 23415313 — intervention group
Group type: COMPARATOR
Intervention: TAC/MMF vs SRL/MMF
Number of subjects: 78
Study 23415313 — intervention group
Group type: COMPARATOR
Intervention: TAC/SRL vs SRL/MMF
Number of subjects: 78
Study 23415313 — intervention group
Group type: COMPARATOR
Intervention: TAC/SRL vs TAC/MMF
Number of subjects: 78
Study 23415313 — intervention group
Group type: COMPARATOR
Intervention: SRL/MMF vs TAC/MMF
Number of subjects: 78
Study 21154196 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OT) infused at a constant rate of 2 mIU/ml from -15 to 60 min before insulin administration
Number of subjects: 10
Study 21154196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 17947611 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg twice daily)
Number of subjects: 45
Study 17947611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 16481458 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) training
Number of subjects: 19
Study 16481458 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study 14564551 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified angiographic protocol (127 patients); 20 mL iodinated contrast, digital subtraction fluoroscopy for 60 sec.
Number of subjects: 391
Study 14564551 — intervention group
Group type: COMPARATOR
Intervention: Standard completion angiograms (264 patients).
Number of subjects: 391
Study 14564551 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified protocol; postoperative CT scans at 6 months.
Number of subjects: 391
Study 14564551 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol; postoperative CT scans at 6 months.
Number of subjects: 391
Study 14564551 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified protocol; postoperative CT scans at 12 months.
Number of subjects: 391
Study 14564551 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol; postoperative CT scans at 12 months.
Number of subjects: 391
Study 14564551 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall morbidity rate.
Number of subjects: 391
Study 14564551 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative mortality rate.
Number of subjects: 391
Study 10625720 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomethiazole (75 mg/kg intravenous infusion for 24 hours)
Number of subjects: 95
Study 10625720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 10625720 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomethiazole
Number of subjects: 95
Study 9184976 — intervention group
Group type: EXPERIMENTAL
Intervention: Erbe electrocautery device
Number of subjects: 57
Study 9184976 — intervention group
Group type: COMPARATOR
Intervention: Conventional electrocautery
Number of subjects: 57
Study 1590670 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral riboflavin therapy
Number of subjects: 0
Study 1590670 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not receiving riboflavin)
Number of subjects: 0
Study 1590670 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (riboflavin and placebo)
Number of subjects: 0
Study 1590670 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin supplementation
Number of subjects: 0
Study 1590670 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin deficiency
Number of subjects: 0
Study 2859871 — intervention group
Group type: EXPERIMENTAL
Intervention: Adimolol 25 mg
Number of subjects: 6
Study 2859871 — intervention group
Group type: EXPERIMENTAL
Intervention: Adimolol 600 mg
Number of subjects: 6
Study 2859871 — intervention group
Group type: EXPERIMENTAL
Intervention: Adimolol 400 mg
Number of subjects: 6
Study 2859871 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 800 mg
Number of subjects: 6
Study 2859871 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 6
Study 2859871 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 400 mg
Number of subjects: 6
Study 2859871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29678756 — intervention group
Group type: EXPERIMENTAL
Intervention: D&C plus NCH gel application (NCH gel group)
Number of subjects: 300
Study 29678756 — intervention group
Group type: COMPARATOR
Intervention: D&C alone (control group)
Number of subjects: 300
Study 30189776 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-narrow sterile exsanguination tourniquet (SET)
Number of subjects: 58
Study 30189776 — intervention group
Group type: COMPARATOR
Intervention: Wide contoured pneumatic tourniquet (PT)
Number of subjects: 58
Study 30189776 — intervention group
Group type: EXPERIMENTAL
Intervention: SET
Number of subjects: 58
Study 30189776 — intervention group
Group type: COMPARATOR
Intervention: PT
Number of subjects: 58
Study 27626473 — intervention group
Group type: EXPERIMENTAL
Intervention: LDE-paclitaxel (175 mg/m2, intravenous administration, 3/3 weeks for 6 cycles)
Number of subjects: 17
Study 27626473 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 17
Study 25197811 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg) in the morning
Number of subjects: 21
Study 25197811 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg) in the evening
Number of subjects: 21
Study 25197811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 22116977 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care (n = 65)
Number of subjects: 126
Study 22116977 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 61)
Number of subjects: 126
Study 20453053 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication and stress management skills training programme
Number of subjects: 96
Study 17664376 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 or 40 mg, depending on age, continued after a previous placebo-controlled study for an average treatment period of 4.5 years.
Number of subjects: 186
Study 17664376 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 186
Study 16236186 — intervention group
Group type: EXPERIMENTAL
Intervention: Haem iron preparation
Number of subjects: 110
Study 16236186 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate (FeSO4)
Number of subjects: 110
Study 16236186 — intervention group
Group type: COMPARATOR
Intervention: Beans-only (control)
Number of subjects: 110
Study 12473512 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil, docetaxel (in patients who have already received paclitaxel), vinorelbine, mitomycin c
Number of subjects: 0
Study 12473512 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel oral therapies
Number of subjects: 0
Study 10209080 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine (50 mg thrice daily)
Number of subjects: 10
Study 10209080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7609291 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal diclofenac 50 mg plus continuous epidural infusion with buprenorphine and bupivacaine
Number of subjects: 80
Study 7609291 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural infusion with buprenorphine and bupivacaine
Number of subjects: 80
Study 2222132 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine sulfate
Number of subjects: 90
Study 2222132 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride
Number of subjects: 90
Study 2222132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 318971 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin 2 g daily in four divided doses for 28 days
Number of subjects: 0
Study 318971 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31505025 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31021036 — intervention group
Group type: EXPERIMENTAL
Intervention: facilitated subcutaneous immunoglobulin (fSCIG)
Number of subjects: 20
Study 31021036 — intervention group
Group type: COMPARATOR
Intervention: conventional subcutaneous immunoglobulin (cSCIG)
Number of subjects: 20
Study 27592520 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (listening to music three days a week for 8 weeks)
Number of subjects: 64
Study 27592520 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 64
Study 27592520 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 64
Study 25613721 — intervention group
Group type: EXPERIMENTAL
Intervention: IIV4-ID
Number of subjects: 3355
Study 25613721 — intervention group
Group type: COMPARATOR
Intervention: IIV3-ID (licensed)
Number of subjects: 3355
Study 25613721 — intervention group
Group type: COMPARATOR
Intervention: IIV3-ID (investigational)
Number of subjects: 3355
Study 25613721 — intervention group
Group type: COMPARATOR
Intervention: IIV3-ID (licensed and investigational)
Number of subjects: 3355
Study 23917748 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 ppb ozone
Number of subjects: 10
Study 23917748 — intervention group
Group type: COMPARATOR
Intervention: filtered air
Number of subjects: 10
Study 21792546 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraprofessional home visitation and parent-infant groups for 1 year
Number of subjects: 0
Study 21792546 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group) with monthly social work contact
Number of subjects: 0
Study 19873915 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at local points of eye (Jingming (BL 1), Tongziliao (GB 1), Shangming (Extra))
Number of subjects: 100
Study 19873915 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Methycobal and Vitamin B1 (medication group)
Number of subjects: 100
Study 17878129 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast Cancer Education Intervention (BCEI) delivered in three face‐to‐face sessions and five monthly follow‐up sessions (three by telephone and two in person)
Number of subjects: 256
Study 17878129 — intervention group
Group type: COMPARATOR
Intervention: Wait control group receiving four monthly attention control telephone calls and the BCEI at month 6
Number of subjects: 256
Study 14679271 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Steps Program
Number of subjects: 5565
Study 10690889 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment group A (4 IU/m2 x day)
Number of subjects: 68
Study 10690889 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment group B (4 IU/m2 x day for the first year, then 6 IU/m2 x day)
Number of subjects: 68
Study 10690889 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment group C (4 IU/m2 x day for the first year, 6 IU/m2 x day for the second year, then 8 IU/m2 x day)
Number of subjects: 68
Study 10690889 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment group C1 (7-year data from group C)
Number of subjects: 68
Study 10690889 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment (mean duration 85.3 months)
Number of subjects: 68
Study 10690889 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 68
Study 9347244 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg t.i.d.
Number of subjects: 65
Study 9347244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 8360391 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthelmintic treatment (Oxantel-Pyrantel; Quantrel) for 22 months
Number of subjects: 0
Study 8360391 — intervention group
Group type: COMPARATOR
Intervention: Control group (children who declined treatment)
Number of subjects: 0
Study 2875439 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive group: systematic desensitization (SYS DENS)
Number of subjects: 120
Study 2875439 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive group: sensory description (SEN DESC)
Number of subjects: 120
Study 2875439 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive group: sensory transformation (ST)
Number of subjects: 120
Study 2875439 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive group: modeling (M)
Number of subjects: 120
Study 2875439 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive group: relaxation (R)
Number of subjects: 120
Study 2875439 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cognitive groups: SYS DENS, SEN DESC, and ST
Number of subjects: 120
Study 2875439 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cognitive groups: SEN DESC, ST, and R
Number of subjects: 120
Study 2875439 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cognitive groups: SEN DESC, R, ST, and Demerol
Number of subjects: 120
Study 2875439 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic group: expected Demerol
Number of subjects: 120
Study 2875439 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic group: did not expect Demerol
Number of subjects: 120
Study 2875439 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic group: placebo
Number of subjects: 120
Study 2875439 — intervention group
Group type: COMPARATOR
Intervention: Control group: no treatment
Number of subjects: 120
Study 30817560 — intervention group
Group type: EXPERIMENTAL
Intervention: NRP Prompt (interactive mobile application providing audiovisual prompts)
Number of subjects: 39
Study 30817560 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard visual aids with NRP Prompt
Number of subjects: 39
Study 30817560 — intervention group
Group type: COMPARATOR
Intervention: Visual aids only (control)
Number of subjects: 39
Study 30572554 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational Emotive Digital Storytelling Intervention (REDStory)
Number of subjects: 0
Study 30572554 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study 26735263 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA featuring real person
Number of subjects: 4
Study 26735263 — intervention group
Group type: COMPARATOR
Intervention: PSA featuring actor
Number of subjects: 4
Study 25169652 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacifier use
Number of subjects: 30
Study 25169652 — intervention group
Group type: COMPARATOR
Intervention: No pacifier use (Control)
Number of subjects: 30
Study 20830502 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib (100 mg once daily) plus docetaxel (100 mg/m² IV every 21 days)
Number of subjects: 64
Study 20830502 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus docetaxel (100 mg/m² IV every 21 days)
Number of subjects: 64
Study 19459523 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPI)
Number of subjects: 569
Study 19459523 — intervention group
Group type: COMPARATOR
Intervention: Histamine-2 receptor antagonists (H2RA)
Number of subjects: 569
Study 17240233 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia (1% lidocaine)
Number of subjects: 204
Study 17240233 — intervention group
Group type: COMPARATOR
Intervention: No local anesthesia
Number of subjects: 204
Study 15562020 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg testosterone enanthate weekly
Number of subjects: 60
Study 15562020 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg testosterone enanthate weekly
Number of subjects: 60
Study 15562020 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg testosterone enanthate weekly
Number of subjects: 60
Study 15562020 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg testosterone enanthate weekly
Number of subjects: 60
Study 15562020 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg testosterone enanthate weekly
Number of subjects: 60
Study 15562020 — intervention group
Group type: COMPARATOR
Intervention: Control group (young men, 19-35 years)
Number of subjects: 60
Study 12244484 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-molecular-weight heparin (MMWH)
Number of subjects: 16
Study 12244484 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 16
Study 12244484 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (enoxaparin)
Number of subjects: 16
Study 10443094 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylocaine injection at the gastrocnemius trigger point (TrP)
Number of subjects: 24
Study 10443094 — intervention group
Group type: COMPARATOR
Intervention: Oral quinine sulfate 300 mg
Number of subjects: 24
Study 7603215 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir (6 mg/kg body weight per day intravenously from postoperative day 1 to day 30, then 6 mg/kg per day Monday through Friday until day 100)
Number of subjects: 250
Study 7603215 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir (10 mg/kg intravenously every 8 h from postoperative day 1 to day of discharge, then 800 mg orally four times a day until day 100)
Number of subjects: 250
Study 7603215 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Number of subjects: 250
Study 7603215 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir
Number of subjects: 250
Study 1695049 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (DDP) alone
Number of subjects: 173
Study 1695049 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (DDP) in combination with Adriamycine (ADM) and Cyclophosphamid (CTX)
Number of subjects: 173
Study 277246 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole for the radiotherapy of Grades 3 and 4 cerebral astrocytoma
Number of subjects: 10
Study 31209192 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (70mg/d) for 72 hours
Number of subjects: 100
Study 31209192 — intervention group
Group type: COMPARATOR
Intervention: Control group (no trimetazidine)
Number of subjects: 100